Bagsværd, Denmark, 11 February 2026 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.

1 Details of the person discharging managerial responsibilities/person closely associated a)Name of the Board member/Executive/Associated PersonKarsten Munk Knudsen 2 Reason for the notification a)Position/statusExecutive Vice President, Chief Financial Officer (CFO) b)Initial notification/AmendmentInitial notification 3 Details of the issuer a)NameNovo Nordisk A/S b)LEI549300DAQ1CVT6CXN342 4 Details of the transaction(s) a)Description of the financial instrument,

type of instrument,

Shares

 

Get the latest news


delivered to your inbox

Sign up for The Manila Times newsletters

By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

  Identification codeNovo Nordisk B DK0062498333 b)Nature of the transactionSale of shares c)Price(s) and volume(s) Price(s)Volume(s)   DKK 315.6026,246       d)Aggregated information  

26,246 shares

DKK 8,283,237.60

 e)Date of the transaction2026-02-10 f)Place of the transactionJANE STREET NETHERLANDS B.V. (JNSI) 

1 Details of the person discharging managerial responsibilities/person closely associated a)Name of the Board member/Executive/Associated PersonKarsten Munk Knudsen 2 Reason for the notification a)Position/statusExecutive Vice President, Chief Financial Officer (CFO) b)Initial notification/AmendmentInitial notification 3 Details of the issuer a)NameNovo Nordisk A/S b)LEI549300DAQ1CVT6CXN342 4 Details of the transaction(s) a)Description of the financial instrument,

type of instrument,

Shares

 

  Identification codeNovo Nordisk B DK0062498333 b)Nature of the transactionSale of shares c)Price(s) and volume(s) Price(s)Volume(s)   DKK 315.70311       d)Aggregated information  

311 shares

DKK 98,182.70

 e)Date of the transaction2026-02-10 f)Place of the transactionCBOE EUROPE – DXE PERIODIC (NL) (BEUP) 

About Novo Nordisk

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Company announcement No 10 / 2026

Attachment